X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at B. Riley in a research note issued on Wednesday, PriceTargets.com reports. B. Riley also issued estimates for X4 Pharmaceuticals’ FY2025 earnings at ($0.53) EPS and FY2026 earnings at ($0.48) EPS.
XFOR has been the subject of a number of other reports. Stifel Nicolaus boosted their price target on shares of X4 Pharmaceuticals from $4.00 to $5.00 in a research report on Wednesday, May 17th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of X4 Pharmaceuticals in a report on Friday, August 11th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $3.50.
X4 Pharmaceuticals Stock Performance
X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.16). During the same quarter in the previous year, the firm earned ($0.60) EPS. Sell-side analysts predict that X4 Pharmaceuticals will post -0.8 earnings per share for the current fiscal year.
In related news, insider Murray Stewart sold 130,056 shares of the stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $1.06, for a total transaction of $137,859.36. Following the completion of the transaction, the insider now directly owns 146,504 shares of the company’s stock, valued at $155,294.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Michael S. Wyzga bought 25,000 shares of the stock in a transaction on Friday, August 18th. The shares were bought at an average cost of $1.20 per share, for a total transaction of $30,000.00. Following the completion of the transaction, the director now owns 76,667 shares of the company’s stock, valued at approximately $92,000.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Murray Stewart sold 130,056 shares of the company’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $1.06, for a total transaction of $137,859.36. Following the transaction, the insider now owns 146,504 shares in the company, valued at $155,294.24. The disclosure for this sale can be found here. Over the last three months, insiders sold 159,157 shares of company stock valued at $197,678. Insiders own 1.08% of the company’s stock.
Institutional Trading of X4 Pharmaceuticals
Large investors have recently modified their holdings of the business. Principal Financial Group Inc. acquired a new stake in shares of X4 Pharmaceuticals in the second quarter valued at approximately $27,000. Grimes & Company Inc. purchased a new position in shares of X4 Pharmaceuticals during the second quarter valued at approximately $29,000. ProShare Advisors LLC purchased a new position in shares of X4 Pharmaceuticals during the second quarter valued at approximately $31,000. Private Advisor Group LLC purchased a new position in shares of X4 Pharmaceuticals during the second quarter valued at approximately $38,000. Finally, State of Wisconsin Investment Board purchased a new position in shares of X4 Pharmaceuticals during the second quarter valued at approximately $46,000. 78.50% of the stock is currently owned by institutional investors and hedge funds.
X4 Pharmaceuticals Company Profile
X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia.
- Five stocks we like better than X4 Pharmaceuticals
- The How and Why of Investing in Biotech Stocks
- Why Ambarella’s 20% Decline is a Strong Signal for New Investment
- How to Buy Cheap Stocks Step by Step
- Why Analysts Love These 2 Car Sales Platforms, And Avoid Dealers
- Learn Technical Analysis Skills to Master the Stock Market
- A Significant Reversal is in Sight for These 5 Med Tech Companies
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.